RGNX
REGENXBIO Inc.
Biotechnology · Healthcare · United States
7.20
close · 2026-10-30
value
11
cheaper than peers11
quality
51
stronger fundamentals51
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 2.72× | 84 |
| price to book | 5.43× | 33 |
| cash flow yield, latest year | -26.6% | 26 |
| cash flow yield, 1 year ago | -36.9% | 22 |
| earnings yield, 1 year ago | -63.7% | 21 |
| earnings yield, latest year | -52.2% | 20 |
| cash flow yield, 2 years ago | -48.0% | 20 |
| cash flow yield, 3 years ago | -50.1% | 19 |
| earnings yield, 2 years ago | -83.6% | 18 |
| earnings yield, 3 years ago | -90.3% | 18 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 405.7% | 90 |
| operating margin | 27.1% | 90 |
| return on equity | -137.6% | 17 |
| debt to equity | 349.0% | 7 |
4 of 4 measures available
Facts
| market cap | $475M |
| free cash flow | -$184.7M |
| employees | 371 |
| first trade | 2015-09-17 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.76 | -4.59 | -6.02 | -6.50 |
| free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M |
| net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M |
| revenue | $170.4M | $83.3M | $90.2M | $112.7M |
| unusual items | $12.2M | $16.6M | $11.3M | $5.4M |